Paolo Tarantino: The BEGONIA ph1/2 trial ages like good wine

Quoting Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, on X/Twitter:

“The BEGONIA ph1/2 trial ages like good wine. At SABCS22, with 7 months of follow up, Dato-DXd+durva had shown an ORR of 73% for 1L TNBC. In the updated abstract at ESMO23, ORR increased to 79%, median PFS exceeded one year (13.8 months). Only 3 cases of ILD (max G2).”

Source: Paolo Tarantino/Twitter.